GPE
Australia Rejects Eisai’s Alzheimer’s Drug Leqembi
Leqembi, Eisai, Alzheimer’s disease, Australia, TGA, drug rejection
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
Eisai Cuts 121 US Jobs in Strategic Restructuring
Eisai, layoffs, restructuring, US operations, pharmaceutical industry, Leqembi, Alzheimer’s disease
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
FDA Moves to Rehire Some Recently Fired Employees Amid Backlash
FDA, layoffs, rehiring, Trump administration, medical device industry, public health agencies
Amgen expands Indian footprint with $200M tech hub
Amgen, India, Technology, Site, Data Science, Aortic Valve Insufficiency, India ‘s
FDA Reverses Course, Rehires Hundreds of Recently Fired Probationary Workers
FDA, probationary workers, rehiring, mass layoffs, federal agencies, Trump administration, Department of Health and Human Services (HHS)
AstraZeneca to acquire FibroGen’s China unit for $160M
China, AstraZeneca, FibroGen, FibroGen ‘s, roxadustat
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry